Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada

Sexually Transmitted Diseases

Volumn 40, Issue 11, 2013, Pages 877-879

  Gratrix, Jennifer ^a   Bergman, Joshua ^b   Egan, Cari ^c   Drews, Steven J ^d   Read, Ron ^c   Singh, Ameeta E ^a,b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b AHE Neuropsychology   (Canada)

^c AHS   (Canada)

^d PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN;

ADULT; ARTICLE; CANADA; FELLATIO; FEMALE; GENETIC POLYMORPHISM; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEISSERIA GONORRHOEAE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SEXUALLY TRANSMITTED DISEASE; TREATMENT FAILURE;

ADULT; ALBERTA; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFIXIME; DRUG THERAPY, COMBINATION; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PHARYNGEAL DISEASES; PHARYNX; RETROSPECTIVE STUDIES; SEXUAL BEHAVIOR; TREATMENT FAILURE;

EID: 84886068333     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000033     Document Type: Article

References (18)

1. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013;309:163-170.
2. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012;61:590-594.
3. Public Health Agency of Canada. 2011. Important Notice VPublic Health Information Update on the Treatment of Gonococcal Infection. Available at: http://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/alert-gono-eng.php. Accessed January 30, 2013.
4. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013;24:85-92.
5. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7:821-834.
6. Kinghorn G. Pharyngeal gonorrhoea: A silent cause for concern. Sex Transm Infect 2010;86:413-414.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Twentieth Informational Supplement M100-S20, Vol. 32 No. 3. Wayne, PA: CLSI, 2010.
8. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004;189:1497-1505.
9. Allen VG, Farrell DJ, Rebbapragada A, et al. Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 2011; 55:703-712.
10. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Available at: http://whqlibdoc.who.int/publications/2012/9789241503501-eng.pdf. Accessed January 30, 2013.
11. Ota K, Fisman D, Itamar T, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with man: A 13 year retrospective cohort study. Clin Infect Dis 2009;48:1237-1243.
12. Martin I, Sawatzky P, Allen V, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012;39:316-323.
13. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995;20(suppl 1): S47YS65.
14. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007;44(suppl 3):S84YS101.
15. Sathia L, Ellis B, Phillip S, et al. Pharyngeal gonorrhea Vis dual therapy the way forward? Int J STD AIDS 2007;18:647-648.
16. Barbee L, Kerani R, Dombrowski J, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013;56:1539-1545.
17. Blumer JL, Reed MD, Kaplan EL, et al. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in Group A streptococcal tonsillopharyngitis: A reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005;116:927-932.
18. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: Time for a pharmacodynamic rethink? J Antimicrob Chemother 2010;65:2141-2148.